Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs are engineered...

Descripción completa

Detalles Bibliográficos
Autores principales: Klampatsa, Astero, Haas, Andrew R., Moon, Edmund K., Albelda, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615330/
https://www.ncbi.nlm.nih.gov/pubmed/28862644
http://dx.doi.org/10.3390/cancers9090115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615330/
https://www.ncbi.nlm.nih.gov/pubmed/28862644
http://dx.doi.org/10.3390/cancers9090115

Ejemplares similares